Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PBLS by emailGet an email when PBLS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PBLS, unsubscribe in one click. Privacy
📣 What PBLS Says Is Next
first half of 2027 · “Expect to share clinical data from additional patients in the first half of 2027 for ACP, a locally aggressive tumor arising near the pituitary gland associated with significant lifelong morbidity and no approved drug therapies, with a conservatively estimated 15-year prevalence of approximately 5,000 to 9,000 patients in the U.S. Additional Wnt-driven tumors”
Company press release, Aug 13, 2026 · SEC filing
first quarter of 2027 · “Anticipate disclosing additional FAP data in the first quarter of 2027 Adamantinomatous craniopharyngioma (ACP)”
Company press release, Aug 13, 2026 · SEC filing
second half of 2026 · “Expect to initiate enrollment in a dedicated clinical cohort evaluating zolucatetide in patients with FAP during the second half of 2026”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PBLS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBLS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.